Lauren Bongiorno is a Diabetic Health Coach, Yoga and Bootcamp Instructor and Nike Influencer. Lauren works with diabetics around the world who want to lower their A1C, achieve more predictable blood sugar numbers, create a stable exercise and nutrition routine, reduce mental stress, and increase their insulin sensitivity for weight loss so that they can take control of their diabetes mind and body and not just live, but thrive. You can follow her journey on Instagram and find out more about her health coaching on her website.
David is the visual creator and motivational figure of @type1livabetic. He was diagnosed with Type 1 Diabetes in 2008 and after going through a rough patch with his Diabetes years later, he wanted to make a difference in the Diabetic community and spread awareness to others with his positive attitude by creating @type1livabetic on Instagram. David posts often on hot topics and social issues in the vast world of Diabetes, all while providing creative photos and helpful information. David has a passion for design and photography and his goal is to become a Diabetes educator and teach others on the importance of spreading awareness and managing T1D, all which are prominent in his posts. David is currently an undergrad student aiming high for finding a common ground between happiness and health.
Bia is the founder of Biabética, an online blog created in 2016 to share information about diabetes in Brazil. She lives in Rio de Janeiro, and was diagnosed with Type 1 diabetes in 2000. She learned to live a happy life with Diabetes, and wants to help other diabetics accept their own condition. Bia graduated with a degree in Public Relations, and recently created a company named Biabética to sell decorative stickers for insulin pumps and glucose meters in Brazil and around the world. Her next step in life will be the graduating with a degree in Nutrition, so she can further help those living with diabetes.
You’re invited! Click to RSVP to attend
The Innovation Awards Recognize Patient Entrepreneurs for Their Innovative and Disruptive Ideas for Management of Diabetes Using Consumer, Medical Devices, or Healthcare Information Technologies
COPENHAGEN, Denmark, Nov. 08, 2017 (GLOBE NEWSWIRE) — Patient Entrepreneur and Founder & CEO of Med Angel BV, Amin Zayani was named the recipient of the 2017 Lyfebulb-Novo Nordisk Innovation Award for his work in addressing the management of diabetes and received a grant of $25,000. Amin Zayani was selected from a group of twelve finalists (which can be found here) after dozens of Award submissions were received from 25 countries. In addition, Linh Le, represented by Malcolm Nason, of Bonbouton and Jen Horonjeff of Savvy Cooperative received second and third place in the competition, and were awarded $15,000 and $10,000 respectively. The winners were selected by an international panel of judges.
The Summit jury was comprised of Magnus Persson, MD, PhD, a board professional, Professor John Nolan, Special Advisor to the President of EASD, Shaukat Sadikot, MD, President of the International Diabetes Foundation, Shomit Ghose, Partner at Onset Ventures (and the jury Chairman), and Vanessa Pirolo, a patient representative. Mr. Ghose, states:
“Diabetes is a global health issue affecting a diverse population. The Lyfebulb-Novo Nordisk Innovation Summit brought together diverse solutions from global innovators. As a venture capitalist, it was exciting for me to see all of the disruptive solutions that came forward.”
Amin Zayani, who took first place, described his reaction at being announced the winner:
“This prize represents a lot of recognition for our company’s mission and we are raising awareness of the importance of properly storing insulin at home. When one of the world leaders in making insulin recognizes the problem as well, it consolidates our case. I’m so happy and proud, this prize motivates me to continue what I’m doing.”
The Lyfebulb-Novo Nordisk Summit and Award spotlights outstanding Patient Entrepreneurs’ innovative ideas to disrupt the future management of Diabetes via consumer products, medical devices, or healthcare information technologies. The twelve finalists attended the 2017 Lyfebulb-Novo Nordisk Innovation Summit November 6-8, 2017 hosted by Novo Nordisk A/S in Copenhagen, Denmark, which provided a unique opportunity for visibility and recognition in this highly competitive arena. For more information please visit Lyfebulb’s website.
Dr. Karin Hehenberger, CEO and Founder of Lyfebulb states:
“This year’s Lyfebulb-Novo Nordisk Innovation Summit in Diabetes saw an increase in number of applications from a wider range of countries than last year. The interaction with the 12 finalists proved rewarding for all parties involved, including the distinguished jury, invited guests, Novo Nordisk, and Lyfebulb leadership. We congratulate the three winners chosen by our diverse jury. We believe, however, that all of the finalists have promising futures in this space, and above all, show that their personal ‘lived experiences’ are strong value-adds to the businesses they are building. Lyfebulb’s concept of empowering patient entrepreneurs and to bridge industry with patient communities was clearly validated through this Summit.”
Senior Vice President for Novo Nordisk Device R&D Kenneth Strømdahl adds:
“Entrepreneurial spirit is fueled by great ideas and passion, and patient communities provide vital insights into how we can foster patient-driven innovation. It was a great pleasure to engage with the 12 finalists and there is no doubt that we are all working towards the same goal to ultimately defeat diabetes.”
For more information, please visit Lyfebulb’s website.
Share2Print November 08, 2017 09:14 ET | Source: Lyfebulb COPENHAGEN, Denmark, Nov. 08, 2017 (GLOBE NEWSWIRE) — Patient Entrepreneur and Founder & CEO of Med Angel BV, Amin Zayani was named the recipient of the 2017 Lyfebulb-Novo Nordisk Innovation Award for his work in addressing the management of diabetes and received a grant of $25,000. Amin Zayani was selected from a group of twelve finalists (which can be found here) after dozens of Award submissions were received from 25 countries. In addition, Linh Le, represented by Malcolm Nason, of Bonbouton and Jen Horonjeff of Savvy Cooperative received second and third place in the competition, and were awarded $15,000 and $10,000 respectively. The winners were selected by an international panel of judges.
The Summit jury was comprised of Magnus Persson, MD, PhD, a board professional, Professor John Nolan, Special Advisor to the President of EASD, Shaukat Sadikot, MD, President of the International Diabetes Foundation, Shomit Ghose, Partner at Onset Ventures (and the jury Chairman), and Vanessa Pirolo, a patient representative. Mr. Ghose, states:
“Diabetes is a global health issue affecting a diverse population. The Lyfebulb-Novo Nordisk Innovation Summit brought together diverse solutions from global innovators. As a venture capitalist, it was exciting for me to see all of the disruptive solutions that came forward.”
Amin Zayani, who took first place, described his reaction at being announced the winner:
“This prize represents a lot of recognition for our company’s mission and we are raising awareness of the importance of properly storing insulin at home. When one of the world leaders in making insulin recognizes the problem as well, it consolidates our case. I’m so happy and proud, this prize motivates me to continue what I’m doing.”
The Lyfebulb-Novo Nordisk Summit and Award spotlights outstanding Patient Entrepreneurs’ innovative ideas to disrupt the future management of Diabetes via consumer products, medical devices, or healthcare information technologies. The twelve finalists attended the 2017 Lyfebulb-Novo Nordisk Innovation Summit November 6-8, 2017 hosted by Novo Nordisk A/S in Copenhagen, Denmark, which provided a unique opportunity for visibility and recognition in this highly competitive arena. For more information please visit Lyfebulb’s website.
Dr. Karin Hehenberger, CEO and Founder of Lyfebulb states:
“This year’s Lyfebulb-Novo Nordisk Innovation Summit in Diabetes saw an increase in number of applications from a wider range of countries than last year. The interaction with the 12 finalists proved rewarding for all parties involved, including the distinguished jury, invited guests, Novo Nordisk, and Lyfebulb leadership. We congratulate the three winners chosen by our diverse jury. We believe, however, that all of the finalists have promising futures in this space, and above all, show that their personal ‘lived experiences’ are strong value-adds to the businesses they are building. Lyfebulb’s concept of empowering patient entrepreneurs and to bridge industry with patient communities was clearly validated through this Summit.”
Senior Vice President for Novo Nordisk Device R&D Kenneth Strømdahl adds:
“Entrepreneurial spirit is fueled by great ideas and passion, and patient communities provide vital insights into how we can foster patient-driven innovation. It was a great pleasure to engage with the 12 finalists and there is no doubt that we are all working towards the same goal to ultimately defeat diabetes.”
For more information, please visit Lyfebulb’s website.
About Lyfebulb
Lyfebulb is a business focused on bridging patient communities with industry, and providing a strong voice to people living with chronic disease by empowering patient entrepreneurs and patient ambassadors. See www.lyfebulbprod.staging.wpengine.com, Facebook, Twitter, Instagram, Karin Hehenberger LinkedIn, and Lyfebulb LinkedIn.
About Novo Nordisk
Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 42,000 people in 77 countries and markets its products in more than 165 countries. For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube
Press Contact for Lyfebulb:
Shepard Doniger
BDCG, Inc.
561-637-5750
sdoniger@bdcginc.com
Lyfebulb showcases and mentors ‘patient entrepreneurs’ – entrepreneurs who are affected by chronic diseases and are building businesses which target those suffering from chronic diseases.
Karin Hehenberger was diagnosed with Type 1 diabetes in 1989, at an early age. Her chronic illness required her to go through kidney and pancreas transplants. With a dual perspective as a patient and a doctor, Dr Karin decided to do something to help other people impacted by chronic illnesses, to work on businesses that will help other patients.
Karin founded Lyfebulb with two close friends and colleagues, Riccardo Braglia, CEO of Helsinn, and Stephen Squinto, Venture Partner at Orbimed and Co-founder of Alexion. The idea was to build an organisation that bridges patients with industry. “After my experience as a medical doctor, healthcare executive, and Type 1 diabetic, I personally understand that there’s a gap in the development of solutions for patients and know the impact patients can have on improving solutions to their quality of care,” Dr. Karin says.
She wanted to showcase individuals who, like her, were not accepting of the role of a passive patient, but willing to take on the challenge of changing the future for themselves and others living with chronic disease. Lyfebulb calls these individuals “patient entrepreneurs” not to be confused with the meaning of ‘patience’. These people are anything but patient, but they are living with a chronic disease or closely related to someone with a chronic disease and they are not just sitting back waiting for solutions. They are out there creating products and solutions that may help them and others in the near term.
Although it is not a requirement that the founders be patients of chronic diseases, they have to be personally affected by diabetes or a chronic illness. They often have the disease themselves, other times a friend or family member is living with the disease. Lyfebulb Entrepreneur Circle features people who have made their disease their career. They identify an issue in their lives with the disease and then they address that issue by creating a product or an entire company. At Lyfebulb, they maintain a blog and are active on social media as a way of building the community and getting valuable information to people living with chronic illness. They have hosted many events in different areas of chronic illness, including diabetes, cancer, and inflammatory bowel disease (IBD), which are informational as well as community building. They hold innovation summits with large companies where they ask patient entrepreneurs to apply, choose 10-12 finalists, and then bring them together to compete for monetary prizes and interact with a pharma leadership, VCs, and thought leaders.
“We have hosted 26 events in the three years since we started Lyfebulb in New York City, Stockholm, and Copenhagen. This year we are hosting our second annual Innovation Summit in Copenhagen, Denmark and next year, we will host another summit/award in another therapeutic area, in addition to diabetes,” adds Dr Karin on their events so far and future plans.
Lyfebulb has entered into a partnership with Novo Nordisk to grow the Lyfebulb Entrepreneur Circle and to establish the Lyfebulb–Novo Nordisk Innovation Award to recognize promising startups founded by patient entrepreneurs. The winner of the 2016 edition of the award was Brianna Wolin, CEO & Co-Founder at Find Your Ditto. Brianna has lived with Type 1 Diabetes and Celiac Disease most of her life. Find Your Ditto is the only mobile platform that connects individuals living with the same chronic illness locally for on-demand, in-person peer support to mitigate feelings of loneliness and depression. Users can find their ‘dittos’ and begin to feel like “it’s not just me.”
Lyfebulb also mentors patient entrepreneurs and they help certain companies secure funding through their network. While they do not have an incubator currently, forming a virtual one is in the pipeline. They are also contemplating on raising a venture fund called Lyfebulb Ventures, but may proceed with making specific investments into companies instead.
Press Contact for Lyfebulb:
Shepard Doniger
BDCG, Inc.
561-637-5750
sdoniger@bdcginc.com
CHALLENGE TIMELINE
6-8 November, 2017
Innovation Challenge
8 November, 2017
Winner Announcement
The Winner
Med Angel BV
Amin lives with T1D since 2006, he is a solar energy engineer by training and a hardware expert by trade. After a frustrating accident in 2013, when his insulin was frozen in the domestic refrigerator, he became discovered a massive flaw in the way medications are stored and handled at home, and decided to found MedAngel to solve this problem. He is currently leading a team of engineers, pharmacists and designers to revolutionise the interaction patient-medication, and bring peace of mind to everyone.
Amin Zayani
CEO & Founder
ABOUT THE SUMMIT AND AWARD
The Innovation Summit will bring together Patient Entrepreneurs with venture capitalists, Lyfebulb founders, Novo Nordisk Device R&D leadership, researchers and engineers, in order to spotlight entrepreneurs’ efforts and ideas, and provide professional discussion, direction, and inspiration.
3 DAYS TO CATALYZE INNOVATION
Innovation Award
Keynotes
Workshops & Discussions
The Future Rooms Experience
THE AWARD
Patient Entrepreneurs have a unique ability to create value-adding disease management solutions beyond therapy. Our aim is to support patient-driven innovation and laser-focus on improving the quality of life for those living with diabetes.
THE PITCH COMPETITION
The pitch competition brings to the stage emerging Patient Entrepreneurs to pitch their invention or idea to Lyfebulb founders, Novo Nordisk R&D device leadership, researchers and engineers, and venture capitalists. Contestants will respond to a round of Q&A by the judging panel. The top three outstanding Patient Entrepreneurs will receive monetary awards to further develop their ideas:
International Judging Panel.
The winners will be chosen by a judging panel made up of international representatives from the diabetes community and gain exposure internationally.
Lyfebulb is a chronic disease-focused, patient empowerment platform that connects patients and industry to support user-driven innovation. Grounded with its strong foundation in diabetes, the company has expanded disease states covered into cancer, inflammatory bowel disease, multiple sclerosis, mental health, migraine and transplantation.
Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity.
Headquartered in Denmark, Novo Nordisk employs approximately 42,000 people in 77 countries and markets its products in more than 165 countries.
For more information visit: Novonordisk.com, Facebook, Twitter, LinkedIn, YouTube
Innovation Award Recognizes One Patient Entrepreneur for Her Innovative Idea for Management of Diabetes Using Consumer, Medical Devices, or Healthcare Information Technologies
NEW YORK, Dec. 07, 2016 (GLOBE NEWSWIRE) — Patient Entrepreneur and Founder & CEO of Find Your Ditto, Brianna Wolin was named recipient of the inaugural Lyfebulb-Novo Nordisk Innovation Award for her work in addressing the management of diabetes. Brianna was selected from a grouping of ten finalists after dozens of Award submissions were received from 15 countries. The selection was made by a panel of judges consisting of international representatives of the diabetes patient community.
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/cad5bf80-ac92-4973-9ba5-3d147b14a7f3.
“To be recognized by an innovative organization such as Lyfebulb and Novo Nordisk, a global pharmaceutical leader in diabetes care, is a true honor and an affirmation that our work to helping change the landscape surrounding isolation and depression in chronic illness communities is fully worthwhile,” said Brianna Wolin. “I’m so proud to have our mission – creating a world where no person living with a chronic illness ever has to feel alone – is highlighted by this award.”
The Lyfebulb-Novo Nordisk Innovation Award spotlights one outstanding patient entrepreneur’s innovative efforts and ideas to better manage chronic disease via consumer products, medical devices, or healthcare information technology.
Brianna Wolin was selected from a distinguished grouping of patient entrepreneur finalists that included:
Shilo Ben-Zeev, Smartzyme, Israel; Jeff Dachis, OneDrop, USA; Shantanu Gaur, MD, Allurion, USA; Matt Loper, Wellth, USA; Charles O’Connell, FitScript, USA; Scott Smith, Socrates, USA; Anna Sjoberg, Anna PS, Sweden; John Sjolund, Patients Pending Ltd, UK; David Weingard, Fit4D, USA; Brianna Wolin, Find Your Ditto, USA.
All finalists attended the Innovation Summit held December 6-7, 2016 hosted by Novo Nordisk in Copenhagen, Denmark. The Summit was designed to provide an opportunity for visibility and recognition in this highly competitive arena as well as professional discussion and inspiration for developing ideas further.
“With the global interest in and success of this first Award and event, we are excited about the future for the Innovation Award to grow and for Lyfebulb and Novo Nordisk to expand and strengthen our relationship,” said Dr. Karin Hehenberger, CEO and Founder of Lyfebulb. “Clearly, this effort demonstrates that patient entrepreneurs play a key role in helping people living with chronic disease. At Lyfebulb, we will continue to uncover and give voice to patient entrepreneurs who must be a part of the solution to chronic disease.”
Senior Vice President for Novo Nordisk Device R&D Kenneth Strømdahl added, “While patient-centered companies such as Novo Nordisk will continue to play an important role in bringing innovative solutions for people living with diabetes, this competition proves that passionate patient entrepreneurs are making a real difference to advance the management and care of a chronic condition such as diabetes.”
More information on the Innovation Award, the winner, the sponsors and Summit, as well as each of the finalists and selection process, can be found on the Lyfebulb Website.
About Brianna Wolin Brianna Wolin is a passionate entrepreneur, biomedical engineer and food blogger. Find Your Ditto, FYD, which began as a student project during her time at the University of Michigan, has earned Brianna several awards at the University as well as recognition by SPARK Ann Arbor, including a fully-funded entrepreneurial bootcamp experience and a commitment to continued guidance. Brianna has lived with Type 1 Diabetes and Celiac Disease the majority of her life. Her food blog, A Different Survival Guide, grew out of her need to cook all of her own low carb, gluten free meals unavailable in campus dining halls. Brianna is the Chief Executive Officer of Find Your Ditto, responsible for engagement with universities and healthcare systems, marketing, legal matters, and company finances.
About Lyfebulb Lyfebulb is an organization focused on bringing innovative products and solutions focused on chronic disease to market. Lyfebulb serves as a bridge between patients and industry, and its mission is to improve the quality of life of those living with chronic disease NOW. See www.lyfebulbprod.staging.wpengine.com, Facebook, Twitter, Instagram, Karin Hehenberger LinkedIn, and Lyfebulb LinkedIn.
About Novo Nordisk Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: hemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 42,300 people in 75 countries and markets its products in more than 180 countries. For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.
Press Contact for Lyfebulb: Shepard Doniger BDCG, Inc. 561-637-5750 sdoniger@bdcginc.com
CHALLENGE TIMELINE
6-8 November, 2017
Innovation Challenge
8 November, 2017
Winner Announcement
The Winner
Med Angel BV
Amin lives with T1D since 2006, he is a solar energy engineer by training and a hardware expert by trade. After a frustrating accident in 2013, when his insulin was frozen in the domestic refrigerator, he became discovered a massive flaw in the way medications are stored and handled at home, and decided to found MedAngel to solve this problem. He is currently leading a team of engineers, pharmacists and designers to revolutionise the interaction patient-medication, and bring peace of mind to everyone.
Amin Zayani
CEO & Founder
ABOUT THE SUMMIT AND AWARD
The Innovation Summit will bring together Patient Entrepreneurs with venture capitalists, Lyfebulb founders, Novo Nordisk Device R&D leadership, researchers and engineers, in order to spotlight entrepreneurs’ efforts and ideas, and provide professional discussion, direction, and inspiration.
3 DAYS TO CATALYZE INNOVATION
Innovation Award
Keynotes
Workshops & Discussions
The Future Rooms Experience
THE AWARD
Patient Entrepreneurs have a unique ability to create value-adding disease management solutions beyond therapy. Our aim is to support patient-driven innovation and laser-focus on improving the quality of life for those living with diabetes.
THE PITCH COMPETITION
The pitch competition brings to the stage emerging Patient Entrepreneurs to pitch their invention or idea to Lyfebulb founders, Novo Nordisk R&D device leadership, researchers and engineers, and venture capitalists. Contestants will respond to a round of Q&A by the judging panel. The top three outstanding Patient Entrepreneurs will receive monetary awards to further develop their ideas:
International Judging Panel.
The winners will be chosen by a judging panel made up of international representatives from the diabetes community and gain exposure internationally.
The Award was open to patient entrepreneurs currently working on an innovative project, which can advance the prevention, management, or care of diabetes. The Award was open to entrepreneurs in every kind of health IT, consumer or medical device area, from every country in the world.
The judging panel will assess the following:
WHAT WERE THE JUDGING CRITERIA?
The judging panel looked for evidence of:
How the invention/product had the potential to improve the lives of people with type 1 or type 2 diabetes?
In what aspects the product or service was unique in the market (not an altered marketed device) and met other demands as well?
Usage of innovative and effective technologies that are scalable.
Ability to meet most of the healthcare challenges (e.g. funding, regulations, requirements for clinical testing, etc.)
Team behind the project.
WHO WAS ELIGIBLE?
If you could answer yes to all of the following questions, you were able to apply for the Lyfebulb Innovation Award:
Do you work on innovative ideas and concepts for better management of diabetes using consumer or medical devices, or healthcare IT?
Are you living with diabetes or have a close relative with diabetes?
Do you have the aspiration to develop your project and to deliver the benefit to others suffering from the same burden?
Are you focusing on your idea or business full-time?
Can you document there is a sound scientific and medical rationale for the idea?
Do you have a strong business case behind the idea?
Lyfebulb is a chronic disease-focused, patient empowerment platform that connects patients and industry to support user-driven innovation. Grounded with its strong foundation in diabetes, the company has expanded disease states covered into cancer, inflammatory bowel disease, multiple sclerosis, mental health, migraine and transplantation.
Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity.
Headquartered in Denmark, Novo Nordisk employs approximately 42,000 people in 77 countries and markets its products in more than 165 countries.
For more information visit: Novonordisk.com, Facebook, Twitter, LinkedIn, YouTube
When I founded Lyfebulb together with Riccardo Braglia, Helsinn Group Vice Chairman and CEO and Steve Squinto, PhD, co-founder of Alexion and Venture Partner at Orbimed in 2014, it was with the broad goal to address the gaps I had experienced during my personal journey with diabetes and as a business woman and medical scientist.
Above all, I wanted to showcase individuals, who like myself, were not accepting of the role of a passive patient, but willing to take on the challenge of changing the future for themselves and others living with chronic disease.
At Lyfebulb we call these individuals “patient entrepreneurs” not to be confused with the meaning of patience. These people are anything but patient, but they are living with a chronic disease or closely related to someone with a chronic disease and they are not just sitting back waiting for solutions, but they are out there creating products and solutions that may help them and others in the near term.
My goal for Lyfebulb is to create a global organization that is patient-centric and functions as the voice for a larger population of patients, who have until this point been vulnerable and receptive rather than strong and proactive. We feel that it is patients’ responsibility and opportunity to be innovators, teachers and influencers.
This is why the Lyfebulb Entrepreneur Circle is so important. Here we feature people who have made their disease their career. They identify an issue in their lives with the disease and then they address that issue by creating a product or an entire company. That inspires me and I know it inspires others. If one cannot become an entrepreneur one can mentor others, one can influence large companies and one can advocate for progress.
Recently, Lyfebulb announced a partnership with global leader in diabetes, Novo Nordisk focused on this very effort. Together we will grow the Entrepreneur circle and we have tangible plans for how to showcase and promote them, for the benefit of others living with diabetes and the entire space. Products and solutions originated by someone who lives with the disease daily will be more applicable and better accepted by the peer population.
In the Lyfebulb pulse, we will feature one of our Rock Stars every two weeks – show-casing their personal story and their company/idea.
Our next step is to build an incubator in NYC, where new patient entrepreneurs can enjoy a creative environment with access to early funding, infrastructure for a start-up and help to take the next steps when they are ready to leave the incubator within 2 years.
